Please use this identifier to cite or link to this item:
http://repository.li.mahidol.ac.th/dspace/handle/123456789/25765
Title: | Comparison of imipenem and ceftazidime as therapy for severe melioidosis |
Authors: | Andrew J.H. Simpson Yupin Suputtamongkol Michael D. Smith Brian J. Angus Adul Rajanuwong Vanaporn Wuthiekanun Paul A. Howe Amanda L. Walsh Wipada Chaowagul Nicholas J. White Mahidol University Sappasitthiprasong Hospital Centre for Tropical Medicine John Radcliffe Hospital Musgrove Park Hospital Malaria Proj./Wellcome Trust Res. L. |
Keywords: | Medicine |
Issue Date: | 1-Jan-1999 |
Citation: | Clinical Infectious Diseases. Vol.29, No.2 (1999), 381-387 |
Abstract: | An open, prospective, randomized, comparative treatment trial was conducted to compare the therapeutic efficacy of high-dose intravenous imipenem and ceftazidime for acute severe melioidosis. Adult Thai patients with suspected acute, severe melioidosis were randomized to receive either imipenem, at a dosage of 50 mg/(kg · d), or ceftazidime, at a dosage of 120 mg/(kg · d), for a minimum of 10 days. The main outcome measures were death or treatment failure. Of the 296 patients enrolled, 214 had culture-confirmed melioidosis, and 132 (61.7%) of them had positive blood cultures. Mortality among patients with melioidosis was 36,9% overall. There were no differences in survival overall (P = .96) or after 48 hours (P = .3). Treatment failure after 48 hours was more common among patients treated with ceftazidime (P = .011). Both treatments were well tolerated. Imipenem is a safe and effective treatment for acute severe melioidosis and may be considered an alternative to ceftazidime. |
URI: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0032777243&origin=inward http://repository.li.mahidol.ac.th/dspace/handle/123456789/25765 |
ISSN: | 10584838 |
Appears in Collections: | Scopus 1991-2000 |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.